{"DataElement":{"publicId":"7209477","version":"1","preferredName":"Gemtuzumab Ozogamicin Administered Instance Count Number","preferredDefinition":"The number of instances gemtuzumab ozogamicin was administered.","longName":"2791130v1.0:7330080v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2791130","version":"1","preferredName":"Gemtuzumab Ozogamicin Administered","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)._The act of having given something (e.g., a medication or test).","longName":"GMTOZ_ADM","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3031382","version":"1","preferredName":"Gemtuzumab Ozogamicin","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","longName":"C1806","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"82FAC8EC-DAB5-00C8-E040-BB89AD432EA4","latestVersionIndicator":"Yes","beginDate":"2010-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-03-29","modifiedBy":"ONEDATA","dateModified":"2010-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5843FC69-E9D6-7081-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7330080","version":"1","preferredName":"Instance Count Number","preferredDefinition":"An occurrence of something._To determine the number or amount of something; the result of this activity._A numeral or string of numerals expressing value, quantity, or identification.","longName":"7330080v1.0","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7330079","version":"1","preferredName":"Instance Count Number","preferredDefinition":"An occurrence of something.:To determine the number or amount of something; the result of this activity.:A numeral or string of numerals expressing value, quantity, or identification. ","longName":"C48364:C25463:C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Instance","conceptCode":"C48364","definition":"An occurrence of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7C2E1ED-A15D-4A30-E053-4EBD850AAE03","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-10","modifiedBy":"ONEDATA","dateModified":"2020-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7C2E1ED-A16E-4A30-E053-4EBD850AAE03","latestVersionIndicator":"Yes","beginDate":"2020-06-10","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-10","modifiedBy":"KUMMEROA","dateModified":"2020-12-21","changeDescription":". 2020-12-21 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What was the number of instan","type":"Preferred Question Text","description":"What was the number of instances gemtuzumab ozogamicin was administered?","url":null,"context":"NHLBI"},{"name":"Specify the number of instances gemtuzumab ozogamicin (Mylotarg) was administered as part of this line of therapy:","type":"Application Standard Question Text","description":"Specify the number of instances gemtuzumab ozogamicin (Mylotarg) was administered as part of this line of therapy:","url":null,"context":"NHLBI"},{"name":"Specify the number of instances gemtuzumab ozogamicin (Mylotarg) was administered as part of this line of therapy:","type":"Alternate Question Text","description":"Specify the number of instances gemtuzumab ozogamicin (Mylotarg) was administered as part of this line of therapy:","url":null,"context":"NHLBI"},{"name":"Specify the number of instances gemtuzumab ozogamicin (Mylotarg/trademark/) was administered as part of this line of therapy:","type":"Alternate Question Text","description":"Specify the number of instances gemtuzumab ozogamicin (Mylotarg/trademark/) was administered as part of this line of therapy:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A112B0A1-DB36-3DC3-E053-F662850A10B0","latestVersionIndicator":"Yes","beginDate":"2020-03-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-17","modifiedBy":"KUMMEROA","dateModified":"2020-12-21","changeDescription":". 2020-12-21 ak OK to release per WZ. System generated def displayed as alt def. 04/30/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}